Your request has been received.
We will send you more information as it becomes available.
Effective January 1, 2025: ASP+6% reimbursement for EXPAREL when billing with code J0666 across all outpatient surgical settings.
Manage pain and minimize opioids after TKA
78% fewer opioids* overall opioid consumption (P=0.0048)
Significantly better PAIN CONTROL cumulative pain scores (P=0.0381)†
Results from a phase 4, double-blind, randomized, controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in a TKA study. Primary end points: area under the curve (AUC) of visual analog scale pain intensity scores 12 to 48 hours postsurgery; total opioid consumption 0 to 48 hours postsurgery. Rescue opioids for pain were available upon patient request. Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness, and muscle spasms.
AUC, area under the curve; TKA, total knee arthroplasty; VAS, Visual Analogue Scale.
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
†Pain measured using visual analog scale.
For adults, a maximum dose of 266 mg (20 mL) is recommended, based on:
For pediatric patients aged 6 to less than 17 years, dosing is weight based: 4 mg/kg (up to a maximum of 266 mg)
For interscalene brachial plexus nerve block in adults, the recommended dose is 133 mg (10 mL), based on a study of patients undergoing rotator cuff repair or total shoulder arthroplasty
For adductor canal block in adults, the recommended dose is 133 mg (10 mL) admixed with 50 mg (10 mL) 0.5% bupivacaine HCl, for a total volume of 20 mL, based on a study of patients undergoing total knee arthroplasty
For sciatic nerve block in the popliteal fossa in adults, the recommended dose is 133 mg (10 mL), based on a study of patients undergoing bunionectomy
See how your peers are using EXPAREL for optimal pain coverage
Multimodal approaches with or without ERAS protocols have demonstrated benefits in knee
Phase 4, multicenter, randomized, double-blind, controlled, parallel-group study comparing the safety and efficacy of infiltration of EXPAREL (n=70) versus standard bupivacaine (n=69) in adults undergoing primary unilateral TKA.
*Opioid intake measured in MED (mg).
†The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
MED, morphine equivalent dosing; TKA, total knee arthroplasty.
Retrospective chart review that analyzed the outcome and feasibility of same-day discharge using an ERAS protocol in the inpatient setting in Medicare patients undergoing TKA (n=337) or THA (n=308).
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
ERAS, enhanced recovery after surgery; THA, total hip arthroplasty; TKA, total knee arthroplasty.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
Check out the news, data, and clinical resources which support the use of EXPAREL in lower extremity procedures
Visualize regional pain control techniques and blocks by surgical sites, explore techniques used in real-world cases, and discover how EXPAREL may supports your patients' recovery after surgery with the EXPAREL InSite tool
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.